TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tharimmune ( (THAR) ) has shared an update.
On November 6, 2025, Tharimmune, Inc. announced the successful closing of a $545 million private placement offering, led by DRW and Liberty City Ventures, to establish a Canton Coin Treasury Strategy. The funds will be used to acquire Canton Coin, support the company’s role as a Super Validator on the Canton Network, and invest in application development, marking Tharimmune as the first publicly traded company supported by the Canton Foundation. This strategic move positions Tharimmune to enhance its operations and industry standing by driving institutional blockchain adoption and creating durable value for shareholders.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Tharimmune, Inc. (NASDAQ: THAR) is a publicly traded company that leverages the Canton Coin (CC) to support the Canton Network’s efforts in digitizing traditional financial markets. The company also operates in clinical-stage biotech research and development.
Average Trading Volume: 10,895,051
Technical Sentiment Signal: Buy
Current Market Cap: $30.36M
For detailed information about THAR stock, go to TipRanks’ Stock Analysis page.